Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[PMLB] [PDX] [OCIP296] Pancreatic Neuroendocrine Carcinoma

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO7873 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing's syndrome.

Project description: Not available

| S-EPMC10265538 | biostudies-literature

Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm

Project description:Pancreatic neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) are rare pancreatic malignant tumors, and comprehensive gene analyses are scarce. In this study, six NECs and six MiNENs were collected, immunohistochemistry for synaptophysin, chromogranin A, INSM1, Ki-67, and Rb was conducted, and KRAS mutational status was examined. Among these cases, comprehensive gene expression analysis of oncogene pathways using nCounter® were performed with six NECs and four MiNENs, and those data were compared with that of three pancreatic ductal adenocarcinomas (PDACs), with that of three normal pancreatic ducts, and with each other. By dividing NEC and MiNEN cases into KRAS-mutated group and KRAS-wild group, the difference of clinicopathological data and gene expression profiling data were examined between the two groups. Compared to the data of normal pancreatic epithelium, all 13 cancer-related pathways were upregulated in PDAC, MiNEN, and NEC group with more upregulation in this order. Compared to the data of PDAC, genes of DNA Damage repair pathway was most upregulated both in NECs and MiNENs. Regarding the difference between KRAS-mutated and KRAS-wild groups, several genes were differentially expressed between the two, where MMP7 was the upregulated gene with highest p-value and NKD1 was the downregulated gene with highest p-value in KRAS-mutated group. From the extent of upregulation of 13 pathways, MiNEN was considered more progressed stage than PDAC, and NEC was considered more progressed than MiNEN. From the comparison of KRAS-mutated and KRAS-wild NECs and MiNENs, several differentially expressed genes were identified in this study.

2024-08-11 | GSE240700 | GEO

Differentiation between G3 pancreatic neuroendocrine tumor and pancreatic neuroendocrine carcinoma based on intratumor and peritumor CT value ratio and abnormal vascular network.

Project description: Not available

| S-EPMC12602241 | biostudies-literature

A Case Report of Mixed Acinar-Neuroendocrine Pancreatic Carcinoma: A Rare Subtype of Pancreatic Cancer

Project description: Not available

| S-EPMC12327934 | biostudies-literature

Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.

Project description: Not available

| S-EPMC7059325 | biostudies-literature

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

Project description: Not available